Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 5,272 matching trials from the live ClinicalTrials.gov search.
Filters: Gainesville, Florida Clear all
Completed Phase 2 Interventional

A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria

NCT06637514
View directory record Official record
Conditions
Phenylketonuria (PKU)
Interventions
JNT-517 Tablet, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Gainesville, Florida • Tampa, Florida • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 24, 2026, 2:47 AM EDT
Completed Not applicable Interventional Results available

Home Video-based Telemedicine to Reduce Hypoglycemia Fear in Parents of Young Children

NCT03914547
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
REDCHiP, ATTN
Behavioral
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
2 Years to 6 Years
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Gainesville, Florida • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 24, 2026, 2:47 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

NCT05103358
View directory record Official record
Conditions
Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
Interventions
nab-sirolimus
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
12 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
159
States / cities
Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 137 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 24, 2026, 2:47 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

NCT06285643
View directory record Official record
Conditions
Parkinson Disease
Interventions
AAV2-GDNF gene therapy, control surgery
Drug · Procedure
Lead sponsor
AskBio Inc
Industry
Eligibility
45 Years to 75 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
34
States / cities
Phoenix, Arizona • Irvine, California • Loma Linda, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 24, 2026, 2:47 AM EDT
Completed Phase 3 Interventional Results available

Diuretic Comparison Project

NCT02185417
View directory record Official record
Conditions
Hypertension
Interventions
Hydrochlorothiazide (HCTZ), Chlorthalidone (CTD)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years and older
Enrollment
20,723 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
69
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fayetteville, Arkansas + 64 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 24, 2026, 2:47 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.

NCT02422940
View directory record Official record
Conditions
Post-ischemic Stroke
Interventions
dalfampridine-ER 7.5 mg, dalfampridine-ER 10 mg
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
62
States / cities
Gilbert, Arizona • Berkeley, California • Carlsbad, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 24, 2026, 2:47 AM EDT
Recruiting No phase listed Observational

Danon Disease Natural History Study

NCT06214507
View directory record Official record
Conditions
Danon Disease
Interventions
No intervention
Other
Lead sponsor
Rocket Pharmaceuticals Inc.
Industry
Eligibility
8 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
9
States / cities
Phoenix, Arizona • La Jolla, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 24, 2026, 2:47 AM EDT
Completed Phase 4 Interventional Results available

Tolvaptan for Ascites in Cirrhotic Patients

NCT01292304
View directory record Official record
Conditions
Ascites, Cirrhosis
Interventions
Tolvaptan
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 27, 2015 · Synced Oct 24, 2026, 2:47 AM EDT
Completed Phase 2 Interventional Results available

Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris

NCT01628549
View directory record Official record
Conditions
Acne Vulgaris
Interventions
50 mg P005672-HCl, Placebo, 100 mg P005672-HCl
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
12 Years to 45 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
38
States / cities
Mobile, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 24, 2026, 2:47 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population

NCT00071448
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin human, insulin lispro, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
6 Years to 18 Years
Enrollment
378 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
76
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Oct 24, 2026, 2:47 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of Once a Day Dose Compared to 2 Doses/Day

NCT00505778
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mesalamine Once-Daily, Mesalamine Twice-Daily
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years and older
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
233
States / cities
Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 24, 2026, 2:47 AM EDT
Completed Phase 4 Interventional Results available

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.

NCT01966107
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease, Moderate to Very Severe COPD
Interventions
Aclidinium Bromide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
3,635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
433
States / cities
Birmingham, Alabama • Florence, Alabama • Foley, Alabama + 334 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 24, 2026, 2:47 AM EDT
Recruiting Phase 3 Interventional

Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1

NCT07486934
View directory record Official record
Conditions
Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy, Steinert Disease, Steinert
Interventions
zeleciment basivarsen (DYNE-101), Placebo
Drug
Lead sponsor
Dyne Therapeutics
Industry
Eligibility
16 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 24, 2026, 2:47 AM EDT
Completed Phase 2 Interventional

Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer

NCT00011999
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, paclitaxel, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
21 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
215
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 165 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 24, 2026, 2:47 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis

NCT03934216
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
BMS-986165, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
31
States / cities
Bristol, Connecticut • Gainesville, Florida • New Port Richey, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 24, 2026, 2:47 AM EDT
Completed Phase 3 Interventional

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

NCT00825955
View directory record Official record
Conditions
Liver Cancer
Interventions
Brivanib, Placebo, Best Supportive Care
Drug · Other · Procedure
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
19
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Loma Linda, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 24, 2026, 2:47 AM EDT
Completed Phase 3 Interventional Results available

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)

NCT02709655
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20mg/day, Placebo
Drug · Other
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
7 Years to 11 Years
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
34
States / cities
Little Rock, Arkansas • Imperial, California • Lemon Grove, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 24, 2026, 2:47 AM EDT
Terminated No phase listed Observational

28mm Ceramic-on-Ceramic Total Hip Replacement Study

NCT01657435
View directory record Official record
Conditions
Non-inflammatory Degenerative Joint Disease, Osteoarthritis, Avascular Necrosis, Post-traumatic Arthritis
Interventions
Ceramax Acetabular System
Device
Lead sponsor
DePuy Orthopaedics
Industry
Eligibility
Not listed
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
12
States / cities
Sacramento, California • Denver, Colorado • Fort Collins, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 24, 2026, 2:47 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143

NCT04122625
View directory record Official record
Conditions
Solid Tumor
Interventions
Debio 1143, Nivolumab
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Gainesville, Florida • Tampa, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 24, 2026, 2:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neulasta in Type 1 Diabetes

NCT00662519
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Neulasta (Pegylated), Placebo, Mixed Meal Tolerance Test (MMTT), Blood test, DNA Test
Drug · Dietary Supplement · Other
Lead sponsor
University of Florida
Other
Eligibility
12 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Oct 24, 2026, 2:47 AM EDT
Completed Not applicable Interventional

Utilization of the TAD Device for Dispensing Pain Medications in Hospice Patients

NCT03940534
View directory record Official record
Conditions
Medication Adherence, Satisfaction, Personal
Interventions
TAD
Device
Lead sponsor
Intent Solutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Gainesville, Florida • Lake City, Florida • Palatka, Florida
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 24, 2026, 2:47 AM EDT
Recruiting Phase 3 Interventional

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

NCT06215716
View directory record Official record
Conditions
NASH With Fibrosis, MASH With Fibrosis
Interventions
Efruxifermin, Placebo
Drug
Lead sponsor
Akero Therapeutics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
198
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 160 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 24, 2026, 2:47 AM EDT
Completed Phase 3 Interventional

A Study of the Clinical Safety, Tolerability, and Efficacy of Zoledronic Acid Compared to an Oral Bisphosphonate

NCT00100555
View directory record Official record
Conditions
Osteoporosis
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 79 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
18
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 24, 2026, 2:47 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Use Muscadine Wine Nutraceuticals to Improve Brain Health, Cognition, and Mental Health

NCT05541887
View directory record Official record
Conditions
Cognitive Performance, Memory, Mood, Anxiety
Interventions
Muscadine Wine Polyphenol, Placebo
Other
Lead sponsor
University of Florida
Other
Eligibility
50 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 24, 2026, 2:47 AM EDT